Jefferies Group LLC reiterated their buy rating on shares of DexCom, Inc. (NASDAQ:DXCM) in a report published on Thursday. They currently have a $91.00 price target on the medical device company’s stock.

Several other brokerages also recently weighed in on DXCM. Robert W. Baird reaffirmed a hold rating and set a $79.00 target price on shares of DexCom in a research note on Sunday, September 10th. BidaskClub raised shares of DexCom from a hold rating to a buy rating in a research note on Wednesday, June 21st. Cowen and Company reissued a buy rating and issued a $90.00 price target on shares of DexCom in a research note on Friday, July 14th. BMO Capital Markets reissued a buy rating and issued a $105.00 price target on shares of DexCom in a report on Thursday, July 13th. Finally, Barclays PLC assumed coverage on shares of DexCom in a report on Friday, September 15th. They issued an equal weight rating and a $76.00 price target for the company. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $72.19.

Shares of DexCom (NASDAQ DXCM) opened at 48.925 on Thursday. The firm has a 50-day moving average of $72.62 and a 200 day moving average of $73.86. DexCom has a 52 week low of $42.62 and a 52 week high of $89.02. The stock’s market cap is $4.23 billion.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. During the same quarter in the prior year, the business posted ($0.24) earnings per share. DexCom’s revenue for the quarter was up 24.3% on a year-over-year basis. On average, equities analysts forecast that DexCom will post ($0.79) EPS for the current fiscal year.

WARNING: “DexCom, Inc. (DXCM) Stock Rating Reaffirmed by Jefferies Group LLC” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/02/dexcom-inc-dxcm-stock-rating-reaffirmed-by-jefferies-group-llc.html.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $71.86, for a total value of $431,160.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,223 shares of company stock worth $2,285,138. Insiders own 1.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its holdings in shares of DexCom by 111.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,471 shares of the medical device company’s stock worth $693,000 after purchasing an additional 4,995 shares during the period. State of Wisconsin Investment Board increased its position in shares of DexCom by 29.0% during the 2nd quarter. State of Wisconsin Investment Board now owns 68,511 shares of the medical device company’s stock worth $5,012,000 after purchasing an additional 15,420 shares during the last quarter. Morgan Stanley increased its position in shares of DexCom by 18.0% during the 1st quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock worth $177,336,000 after purchasing an additional 319,631 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of DexCom by 9.0% during the 2nd quarter. Victory Capital Management Inc. now owns 146,661 shares of the medical device company’s stock worth $10,729,000 after purchasing an additional 12,135 shares during the last quarter. Finally, Credit Suisse AG increased its position in shares of DexCom by 0.3% during the 1st quarter. Credit Suisse AG now owns 302,130 shares of the medical device company’s stock worth $25,599,000 after purchasing an additional 791 shares during the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.